Patents Assigned to Black Cat Bio Limited
  • Publication number: 20230226138
    Abstract: The invention provides a pharmaceutical composition and methods for the treatment of a respiratory disease that results from a viral infection. The pharmaceutical composition can include a peptide that interferes with the Src family kinase-Androgen receptor interaction (i.e., an “SA inhibitor”). The composition can also include Niacin or a Niacin derivative and/or a DNase I or fragment or derivative. The pharmaceutical composition can prevent the development of Acute Respiratory Distress Syndrome (ARDS) associated with Corona vims infection and allow the host adaptive immune response to overcome the infection.
    Type: Application
    Filed: May 28, 2021
    Publication date: July 20, 2023
    Applicant: Black Cat Bio Limited
    Inventor: Mark Eccleston